New Hope for People With Asthma & Eczema
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
New understanding of a receptor key to allergic responses and anaphylaxis in conditions like asthma could offer a new treatment target for sufferers of a variety of conditions.
This the promise of a study by researchers from China's Shenzhen and Wuhan universities, which have identified a mechanism that sustains the release of allergy-stimulating molecules from cells.
Allergic conditions like asthma (affecting around 28 million people in the US) and eczema (31.6 million) have been on the rise in recent decades.
The diseases are triggered by a type of white blood cell called mast cells, which release inflammatory molecules that promote allergic responses and create symptoms like itching, swelling and difficulty breathing.
An illustration of an activated mast cell releasing histamine.
An illustration of an activated mast cell releasing histamine.Allergic reactions begin when antibodies called 'lgE' produced by the immune system interact with 'FcεRI'—a receptor involved in allergies and parasite immunity—and antigens (a substance causing the immune system to react) on mast cells. This, the researchers explained, "set[s] the stage" for the release of allergic mediators.
While scientists have considered targeting FcεRI as a promising treatment approach, it has so far been challenging to implement in the clinic.
In the new study, however, the researchers focused on an enzyme called USP5, which controls the turnover of proteins and has been linked to inflammatory diseases like gum disease.
They discovered that mast cells are dependent on USP5 to release allergy signaling molecules called histamine (hence common allergy medications called antihistamines) and β-hexosaminidase in response to lgE and antigen.
The discovery, the researchers wrote, demonstrates "that USP5 may be an important target in the treatment of type I allergic diseases."
Type I allergic diseases include hay fever, food allergy, anaphylaxis, most types of asthma and urticaria.
"They are all IgE mediated reactions that involve mast cells as a shared target, but there are multiple pathways that contribute to their severity so it's not as simple as blocking one receptor, but it could be a useful addition to current treatment options," Dr. Elena Salagean, a consultant allergist at Holistic Allergy who was not involved in the present study, told Newsweek.
Promisingly, in a mouse model of the potentially life-threatening and rapid allergic reaction, anaphylaxis, knocking out USP5 or treatment with the USP5 inhibitor called WP1130 was found to prevent mast cells from releasing the molecules and weakened allergic reactions.
"The study shows a new potential target in reducing the release of histamine following contact with an allergen. Reducing histamine release from mast cells by blocking enzyme USP5 that's inside the mast cells means that less histamine will be released, so allergic reactions might be much milder," Dr. Salagean observed.
"Previous studies have tried to block the whole of the mast cell receptors, with varying success. Rather than trying that, the novel part in this study is that it's targeting the receptor machinery, an enzyme called USP5 inside the cells, and by doing so, it affects how well this receptor works."
Patient injecting let with auto epinephrine injector.
Patient injecting let with auto epinephrine injector.
Getty Images/AndreyPopov
The research team also revealed that the interaction between IgE and FcεRI binding caused USP5 to perform a process called deubiquitylation, removing molecules from proteins.
The biochemical modification further increased the stability of FcεRI, making the allergic reaction worse in terms of both strength and the time it lasts.
"Current treatments work through various different ways, mostly blocking the downstream effects of mast cell activation. Antihistamines and steroids also block certain mediators, while biologics block chemicals and other enzymes in the allergy pathway," explained Dr. Salagean.
"A USP5 inhibitor would be a direct blocker that works upstream at the control system of the mast cell receptors. By blocking this, it could reduce several mediators at the same time and reduce the strength of the mast cells response to an allergic reaction."
Anaphylaxis is currently primarily treated with epinephrine (adrenaline), which can be administered with an auto-injector like an EpiPen, as well as urgent medical care.
"It's all still early animal study findings but if one can design a drug that specifically targets and inhibits the USP5 enzyme, then it might have real potential. The difficulty lies in delivering it to right cells and making it selective enough, so it doesn't affect other enzymes or pathways at the same time. It's a long way out from being relevant to patients yet," added Dr. Salagean.
Do you have a tip on a health story that Newsweek should be covering? Do you have a question about allergy treatments? Let us know via health@newsweek.com.
Reference
Zhou, Z.-W., Xu, X.-T., Liang, Q.-N., Zhou, Y.-M., Hu, W.-Z., Liu, S., Jiao, Y.-X., Zhang, S.-C., Ji, K., & Chen, J.-J. (2025). USP5 deubiquitylates and stabilizes FcεRIγ to enhance IgE-induced mast cell activation and allergic inflammation. Science Signaling, 18(799). https://doi.org/10.1126/scisignal.adr3411
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
11 hours ago
- Newsweek
Warning Issued After State Sees First Brain-Eating Amoeba Case in 3 Years
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. After a rare brain infection was confirmed in a Missouri resident, health officials warned recreationists across the state to assume the brain-eating amoeba that caused the infection is present in any warm freshwater they visit. Newsweek reached out to the Missouri Department of Health and Senior Services via email for comment. Why It Matters The infection comes as Jaysen Carr, a 12-year-old boy from South Carolina, died on July 18 after being exposed to Naegleria fowleri while swimming in Lake Murray. The incident has drawn attention to the dangers of this rare but deadly amoeba that thrives in warm freshwater during the summer. Missouri health officials confirmed the same infection has landed a Missourian in intensive care, with the source of exposure currently under investigation. What To Know Missouri health officials made the announcement on Facebook earlier this week. "We have confirmed a rare brain infection in a Missourian caused by an ameba (also spelled amoeba) called Naegleria fowleri. The infection is known as primary amebic meningoencephalitis (PAM) - it is not contagious, but it is deadly. The patient is being treated in the ICU," the post said. Using the direct fluorescent antibody (DFA) staining technique, this photomicrograph depicts the histopathologic characteristics associated with a case of amebic meningoencephalitis due to Naegleria fowleri parasites. Using the direct fluorescent antibody (DFA) staining technique, this photomicrograph depicts the histopathologic characteristics associated with a case of amebic meningoencephalitis due to Naegleria fowleri parasites. Smith Collection/Gado/Getty Images/Getty It is the first such infection in three years for Missouri. Between 1962 and 2024, there have been 167 reported cases of PAM in the United States, two of which occurred in Missouri. One was in 1987 and another in 2022. The infection is almost always fatal, and only four people in the U.S. have survived the infection, the Centers for Disease Control and Prevention (CDC) said. An investigation has been launched into the source of exposure for the Missouri patient, but health officials said "preliminary information implies the patient may have been participating in water activities at the Lake of the Ozarks days before becoming ill." "Recreational water users should assume that Naegleria fowleri is present in any warm freshwater across the U.S.; however, infection remains extremely rare," the post said. People can reduce their risk of infection by taking several precautions, including holding their nose shut or using nose clips, keeping their head above water, avoiding water activities when water temperatures are higher, and avoiding digging in sediment. Early symptoms of the infection include headache, fever, nausea, and vomiting. It progresses rapidly and usually causes a coma or death after five days, the CDC said. Most people die within 18 days of symptoms beginning. What People Are Saying Missouri Department of Health & Senior Services in a post on Facebook: "Although rare, infection can occur when water containing Naegleria fowleri enters through the nose from freshwater. The ameba travels up the nose to the brain where it destroys brain tissue. It is important to remember that this infection isn't contagious and can't be contracted by swallowing water." The CDC's webpage about the infection: "Brain infections caused by Naegleria fowleri usually occur after someone goes swimming or diving in a lake, river, or other fresh water during summer months. Infections often happen when it's been hot for long periods, resulting in higher water temperatures and lower water levels. A few infections have occurred when people used tap water that contained Naegleria fowleri to rinse their sinuses or cleanse their nasal passages." What Happens Next Since the amoeba thrives in freshwater with temperatures between 80 and 115 degrees Fahrenheit, the rare infections could become more common as climate change warms the environment. People recreating in warm freshwater across the U.S. should take accurate precautions.
Newsweek
13 hours ago
- Newsweek
Map Shows Where Power Outages Are Most Common in the US
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. From Winter Storm Blair to Hurricane Beryl in Texas and the more recent Connecticut thunderstorms, power outages from severe weather events have become an increasingly common reality across the United States in recent years. A nationwide study from the Urban Resilience AI Lab at Texas A&M University has produced the first-ever Power System Vulnerability Index (PSVI)—a classification of each county identifying those most at risk of frequent and prolonged blackouts. "Using data from Oak Ridge National Laboratory, we studied the effect of weather events on the frequency and duration of nationwide power outages over the past 10 years," explained paper author and civil engineer Junwei Ma in a statement. "The dataset included over 179 million data points sorted by time and location, allowing us to create the PSVI." Where US Power Outages Hit Hardest The researchers' analysis examined outages between 2014 and 2023 across 3,022 U.S. counties, covering 96 percent of the contiguous United States. Results showed a steady nationwide rise in power system vulnerability, with 318 counties across 45 states now considered "hotspots" for high risk. Regions Most Vulnerable to Blackouts According to the PSVI data, the most vulnerable U.S. regions include: The West Coast, particularly California and Washington The East Coast, including Florida and the Northeast megalopolis The Great Lakes corridor (Chicago–Detroit) Gulf Coast areas of Texas The average county experienced outages lasting 7.3 days per year—roughly 2 percent of the year without power—with an outage occurring about once a week. Since 2019, outage duration, frequency, and scale have increased by around 20 percent annually. Why Vulnerability Is Rising Researchers linked many spikes in vulnerability to extreme weather disasters such as wildfires in California, hurricanes in Florida, and the 2021 Texas winter storm. However, non-weather factors, including aging electrical grids, rising energy demand, and urban development density, also play a major role. Urban counties, with dense populations and infrastructure, showed significantly higher vulnerability than rural areas. "Dense street trees, heavy electricity demand, and concentrated infrastructure mean cities are hit harder and recover more slowly from outages," Ma explained. How the Power System Vulnerability Index Works The PSVI was built using explainable A.I., a machine learning method that weighs outage frequency, intensity, and duration to produce a county-by-county score. This publicly available tool allows users to explore vulnerability trends over the past decade and compare risks nationwide. "We're turning 179 million messy outage logs into a roadmap for prevention—showing each county whether its biggest pain point is too many outages, too long, or too large," paper author and civil engineer professor Ali Mostafavi told Newsweek. Why It Matters The team also warned that many A.I. data centers and critical facilities are located in high-risk zones, underscoring the need for targeted investment in resilient infrastructure as severe weather events are expected to become more frequent. "The data show a clear pattern: U.S. power outages are becoming more frequent, longer, and clustered in hotspot counties," Mostafavi said. "By turning high-frequency outage logs into a county-level Power-System Vulnerability Index, we see not only where the grid struggles, but why—whether the main issue is too many events, too many customers affected, or restorations that take too long. "Without targeted upgrades, today's chronic pockets will intensify during climate extremes." The index represents the first transparent, nationwide, county-level view of grid vulnerability built from high-frequency, utility-reported outages, Mostafavi continued. "It moves the conversation from anecdotes to comparable metrics every policymaker can understand." He concluded: "With climate extremes intensifying and electrification accelerating, leaders need clear, data-driven targets for hardening the grid and protecting residents." Do you have a tip on a science story that Newsweek should be covering? Do you have a question about power outages? Let us know via science@ Reference Ma, J., Li, B., Omitaomu, O. A., & Mostafavi, A. (2025). Establishing nationwide power system vulnerability index across US counties using interpretable machine learning. Applied Energy, 397.
Newsweek
14 hours ago
- Newsweek
Diabetes Discovery Reduces 'Life Threatening' Complication Risk
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The discovery of a new biological pathway may explain why people with type 2 diabetes are twice as prone to dangerous blood clots—putting them at risk of heart attack and stroke. This is the conclusion of researchers from the University of Sydney, who say their findings may pave the way for new treatments that reduce this danger. "People with type 2 diabetes have a higher risk of heart attacks and strokes. Part of the reason for this is that their platelets are hyper-reactive," paper author and hematologist professor Freda Passam told Newsweek. Platelets are small cell fragments found in our blood that form clots to help stop bleeding. The high levels of blood sugar seen in diabetes, however, cause biochemical changes that make them "stickier", Passam explained, so they can clot when not needed to. The hematologist continued: "Drugs like aspirin prevent platelets from clotting, but are three times less effective in people with type 2 diabetes. Understanding why platelets are more active in diabetes opens the door to develop drugs that target this newly discovered pathway." In their study, the team found that the levels of a protein called "SEC61B" is significantly increased in the platelets—the tiny blood cells that help form clots—of people with type 2 diabetes. The protein appears to disrupt calcium balance inside platelets, making them more likely to clump together and form clots, the researchers explained. The researchers found that blocking SEC61B activity with an antibiotic called anisomycin reduced platelet clumping in both human samples and animal models. Smiling woman checking her blood sugar levels. Smiling woman checking her blood sugar levels. JLco -Around 1 in 10 Americans (more than 38 million people) live with diabetes, of which 90–95 percent have type 2, which occurs when insulin doesn't work properly or there's not enough of it. While type 2 diabetes typically develops in people aged 45 and over, children, teens and young adults are increasingly developing the condition as well. "People living with type 2 diabetes are vulnerable to increased risk of blood clots," Passam said in a statement. "These exciting findings identify a whole new way to reduce this risk and help prevent life-threatening complications like heart attack and stroke." In their study, the team analyzed both human and mouse platelets, discovering that SEC61B contributes to calcium leakage from the platelets' stores, making the cell fragments more reactive. The Australia-based researchers noted that the condition is "more prevalent in Aboriginal and Torres Strait Islander peoples and in rural and regional communities." "Cardiovascular disease is a leading cause of death in this group, partly due to the heightened activity of platelets—the tiny blood cells that help form clots," they explained. "This heightened platelet sensitivity to clotting also makes traditional anti-coagulant treatments less effective in people with type 2 diabetes, limiting the options to reduce the risk of cardiovascular disease." Treatments targeting SEC61B are still in early stages. However, the researchers believe pre-clinical trials in animals could begin within 1–2 years, with potential therapies for patients likely to be available in the next decade. Do you have a tip on a health story that Newsweek should be covering? Do you have a question type 2 diabetes? Let us know via health@ Reference Kong, Y. X., Rehan, R., Moreno, C. L., Madsen, S., Zhang, Y., Zhao, H., Qi, M., Houlahan, C., Cartland, S. P., Robertshaw, D., Trang, V., Ong, F. J. L., Liu, M., Cheng, E., Alwis, I., Dupuy, A., Cielesh, M., Cooke, K. C., Potter, M., Stӧckli, J., Morahan, G., Kalev-Zylinska, M., Rondina, M. T., Schulman, S., Yang, J., Neely, G. G., Schoenwaelder, S., Jackson, S., James, D., Kavurma, M. M., Hocking, S., Twigg, S. M., Weaver, J., Larance, M., & Passam, F. H. (2025). SEC61B regulates calcium flux and platelet hyperreactivity in diabetes. Journal of Clinical Investigation.
